This webinar will discuss WuXi STA’s practice on overall RSM strategy, focusing on: Starting material evolution, RSM designation, Risk mitigation for potential regulatory push-back
Watch Now
Charles River
Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Therapeutic approaches for Parkinson’s disease are either focused on disease modification (a-synuclein or MPTP models) or symptom management (haloperidol or 6-OHDA models). Our scientists have validated available PD models for changes in fine motor skills, L-dopa-induced dyskinesias, drug-induced jaw movements, and non-motor endpoints such as cognition, constipation, and EDS. Additionally, we have also tested dopamine and other neurotransmitter levels in brain compartments of rodent and large animal models via microdialysis sampling.
Watch Now
In the realm of DNA sequencing, technology developers contribute to advancement in important ways, by building increasingly fast-moving tools that untangle the intricacies of the human genome, and by constructing analytics platforms to wade through the resulting mountains of genetic data.
Watch Now
pharmtech
Economic performance could soon replace compliance as the leading quality goal for pharmaceutical companies.
According to the 2019 Pharma Quality Outlook Survey, 66% of industry executives named compliance as a top goal, down 10% from last year. Meanwhile, more than one-third (39%) say that economic performance is now their top objective, a 4% increase.Join Sparta System's Steve McCarthy, VP of Digital Innovation, as he discusses key findings from this year's survey, which included responses from 161 professionals.
Watch Now